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Prostate cancer (PCa) progression depends on continued
androgen receptor activity [1,2]. Androgen receptor activation
occurs through the binding of the potent androgens, testosterone
and dihydrotestosterone (DHT), which has been shown to promote
malignant cell growth [3]. Androgen deprivation therapy (ADT),
either by medical or surgical castration, is the treatment for
patients with advanced disease [4]. However, in most cases, 
although the cancer initially responds to ADT, after time, it 
becomes resistant, and castration-resistant prostate cancer (CRPC) 
develops, which is the cause of nearly all PCa deaths [5–7]. In 
2016 in the United States, the number of new PCa cases is 
estimated to be 180,000, with about 26,000 PCa-related deaths, 
making prostate cancer the most frequently diagnosed cancer and 
the second-leading cause of cancer death in men [8].
Abiraterone [abi; 17-(3-pyridyl)-androsta-5,16-dien-3b-ol] is a 
17-heteroazole steroidal compound and a potent inhibitor of 
steroid 17a-hydroxylase/17,20-lyase (CYP17A1), an enzyme re-
quired for androgen synthesis [9]. Abi’s structure makes it a potent 
CYP17A1 inhibitor, and the double bond at C16 is necessary for
functionally irreversible inhibition of the enzyme [10–12]. Abi is
administered as the prodrug, abiraterone acetate (AA), for the
treatment of CRPC and prolongs survival for these patients [13–15].
In 2011, the United States Food and Drug Administration (FDA)
approved AA in the post-chemotherapy setting, and in December
2012 it approved the use of AA for patients with chemotherapy-
naïve CRPC [16]. Prednisone is administered with AA to block
mineralocorticoid excess that occurs with the simultaneous
inhibition of cortisol synthesis [17,18].
It has been reported that the main circulating Abi metabolites
are abiraterone sulfate and N-oxide abiraterone sulfate [19]. We
have recently shown that Abi is converted by 3b-hydroxysteroid
dehydrogenase (3b-HSD) to its D4, 3-keto congener (D4-abirater-
one; D4A) [20] both in vitro and in vivo. The steroid A and B rings of
D4A (Fig. 1) are identical to that of testosterone and androstenedi-
one, which enables further metabolism of D4A [21]. Either the 5a-
reductase or 5b-reductase enzymes could initiate the downstream
metabolism of D4A. The 5a-reduced metabolites are 3-keto-5a-
Abi, 3a-OH-5a-Abi and 3b-OH-5a-Abi, while the corresponding
5b-reduced metabolites are 3-keto-5b-Abi, 3a-OH-5b-Abi and
3b-OH-5b-Abi (Fig. 1).
The separation of the Abi metabolites and the parent Abi
compound is expected to be difficult, given their structural
similarities. Here, we describe and validate a novel method for
Fig. 1. Steroidogenic enzyme metabolism of abiraterone and structure of the resultant metabolites. 3b-HSD: 3b-hydroxysteroid dehydrogenase, 5a-Reductase: steroid 5a-
reductase, 5b-reductase: steroid 5b-reductase, 3a-HSD: 3a-hydroxysteroid dehydrogenase.
the determination of Abi and its 7 metabolites (Fig. 1) in human
serum. Separation of all diastereomeric metabolites was achieved
using a reversed-phase chromatographic technique, not requiring
a chiral column. We demonstrated that all seven steroidal Abi
metabolites are present in serum samples from patients with CRPC
undergoing treatment with AA [21].
2. Experimetal
2.1. Materials
Abiraterone and its seven metabolites 3-keto-D4-Abi, 3-keto-
5a-Abi, 3a-OH-5a-Abi, 3b-OH-5a-Abi, 3-keto-5b-Abi, 3a-OH-
5b-Abi and 3b-OH-5b-Abi were synthesized as described
previously [21]. The internal standard (abiraterone-d4) was
purchased from Toronto Research Chemicals, (Toronto, Canada).
Methanol, acetonitrile, water, and formic acid were LC–MS grade,
methyl tertiary butyl ether (MTBE) was HPLC grade and all were
from Fisher Scientific (Fair Lawn, NJ). Double charcoal-stripped
human serum (Golden West Biological Inc., Temecula, CA) was
used for all samples in the validation studies (controls, calibrators)
which were processed by spiking with known concentrations of
the analytes.
2.2. Preparation of standards and quality control (QC) samples
The stock solutions (1 mg/mL) of Abi and its metabolites were
prepared by dissolving the synthesized powder in 100% methanol.
These solutions were further diluted with methanol:H2O, 1:1, and
then mixed in one flask to prepare the working standard at
concentration of 5.0 mg/mL Abi and 0.25 mg/mL for each metabo-
lite. Freshly prepared working standard was used to prepare the
serum calibrators and serum quality control samples, all of which
contained appropriate concentrations of all the analytes. Quality
control (QC) samples were prepared at three levels, based on the
lower limit of quantitation (LLOQ) and the upper limit of
quantitation (ULOQ): QC Low (3x LLOQ), QC Mid (half ULOQ),
and QC High, which is 80% of ULOQ. The final concentrations of the
calibrators and quality control in serum are listed in Table 1. The
internal standard stock (2 mg/mL) was prepared by dissolving the
stock powder in 100% methanol and further diluting it with
methanol:H2O, 1:1 to a final concentration of 1.25 mg/mL. Stock
and working standard solutions were stored at 20 C, and the
calibrators with quality controls were freshly prepared through the
validation.
2.3. Sample preparation
Each calibrator, quality control and patient serum sample was
taken through the following sample preparation steps. The
analytes were extracted from human serum using a liquid–liquid
extraction procedure. 100 mL of serum with spiked analytes was
placed in a glass tube, and 20 mL of 1.25 mg/mL internal standard
working solution was added. The samples were vortexed for 30 s.
After addition of 2 mL MTBE, the samples were vortexed for 1 min.
The samples were then centrifuged for 5 min at 4000 rpm at 4 C.
The organic layer was transferred to another tube and evaporated
to dryness under nitrogen at 40 C. The dried extract was then
reconstituted with 300 mL 1:1 methanol:H2O, and 200 mL was
transferred to an HPLC vial.
2.4. Instrumentation and data analysis
The LC–MS/MS system was an ultra-pressure liquid chroma-
tography (UPLC) system (Shimadzu Corporation, Japan), consisting
of a LC-30AD solvent delivery system, a DGU-20A5R vacuum
degasser, a CTO-30A thermostated column oven, SIL-30AC auto-
sampler, and a system CBM-20A controller, that was coupled with a
Qtrap 5500 mass spectrometer (AB Sciex, Redwood City, CA). Data
acquisition and processing were performed using Analyst software
(version 1.6.2) from AB Sciex. The peak area ratio of the analyte
over the internal standard was used for quantification purposes.
2.5. UPLC–MS/MS conditions
Separation of drug metabolites was achieved using a Zorbax
Eclipse Plus C18 column 150 mm x 2.1 mm, 3.5 mm (Agilent, Santa
Clara, CA) at 40 C with an isocratic mobile phase consisting of 35%
A (0.1% formic acid in water) and 65% B (0.1% formic acid in
methanol:acetonitrile, 60:40), at a flow rate of 0.2 mL/min. Sample
injection volume was 10 mL, and analytical run time was 13 min.
The mass spectrometer was operated in positive ion mode using
an electrospray ionization (ESI) source. Tuning parameters were
optimized for the Abi metabolites and internal standard by
infusing a solution containing 200 ng/mL of each analyte. Nitrogen
was used as the nebulizing (40 L/min) agent and drying gas (30 L/
min). Ion spray voltage and nebulizer temperature were regulated
at 2500 V and 500 C, respectively. All the analytes have the same
declustering potential (120 V), collision energy (60 V), entrance
potential (10 V) and collision exit potential (13 V). The analytes
were quantified using multiple reaction monitoring (MRM) with
the mass transitions for each compound as listed in Table 2.
2.6. Method validation
The method was validated following the US FDA guidance for
bioanalytical method validation [22]. The validation parameters
evaluated were linearity, accuracy and precision, selectivity,
recovery, matrix effect, and stability.
Table 1
Calibrators and quality control samples preparation and final concentration.
Sample Volume of Working
Standard (mL)
Final Volume (mL) Final Concentration in
Serum ng/mL
Abi Metabolites
Cal.1 20 10 2 0.1
Cal. 2 40 10 4 0.2
Cal. 3 120 10 12 0.6
Cal. 4 300 5 60 3
Cal. 5 600 5 120 6
Cal. 6 1400 5 280 14
Cal. 7 2000 5 400 20
QC Low 60 10 6 0.3
QC Mid 1000 5 200 10
QC High 1600 5 320 16
Table 2














Abiraterone-d4 (IS) 354.4 160.1
IS = internal standard.
2.6.1. Linearity
Six calibration curves were constructed in same serum matrix
for each analyte to assess the linear range. The ratio of the analyte
peak area over the internal standard peak area was plotted versus
the nominal concentration. The correlation was then fit by linear
regression, applying a weighting factor of 1/x. To assess selectivity,
blank and zero (blank spiked with internal standard) samples were
prepared with each calibration curve. The calibration curve
consisted of 7 non-zero points with single repeat for each point.
Based on the FDA guidelines, the acceptable deviation from the
nominal concentration is <20% for the LLOQ calibrator and <15%
for the other calibrators. Validation of the calibration curve
requires 67% of the calibrators, including LLOQ and ULOQ, being
within these acceptance criteria.
2.6.2. Accuracy, precision, and LLOQ
In order to determine the accuracy and precision, QC samples
(LLOQ, low, mid, and high) were run. Intra-day precision was
determined with five replicates and inter-day precision was
determined running one of each QC sample on 3 separate days.
Accuracy was determined by how close the mean of the intra-day
QC sample results were to the nominal value. The method is
considered accurate if the measured concentration is within 85–
115% (80–120% for LLOQ) of the expected value. The acceptable
precision criterion is a coefficient of variation percent (CV%) of the
QC sample analyte concentration being no more than 15% (LLOQ
not more than 20%).
2.6.3. Selectivity
Single runs of six different serum batches were used to study
the selectivity of the method. To insure that the samples were free
of interference, LLOQ samples were prepared and compared to the
corresponding blank samples. The requirement of LLOQ is to be at
least 5 times the peak height (or peak area) of any peak detected in
the blank samples at the same retention time of the analyte.
2.6.4. Recovery
Relative recovery was assessed by calculating the ratio of the
analyte/internal standard peak area in spiked samples before
extraction over the analyte/internal standard peak area in spiked
samples after extraction. Three QC samples (low, mid, and high)
were determined. Each of the three QC samples, including both the
pre- and post-extraction samples were assayed in triplicate. The
FDA criterion for acceptable recovery results need to be consistent,
precise and reproducible, as assessed by the coefficient of variation
for each QC sample type being no more than 15%. The CV% was
calculated using this formula CV% = [(DX/X)2 + (DY/Y)2)]1/2, where
DX is the standard deviation for the pre-extraction samples, X is
the mean area ratio of pre-extraction samples, DY is the standard
deviation for the post-extraction samples, and Y is the mean area
ratio of post-extraction samples.
2.6.5. Matrix effect
Matrix effect, calculated as a matrix factor percent (MF%), was
assessed as a ratio of peak area ratio of spiked analyte/internal
standard determined for QC low sample after extraction (n = 18)
over the peak area ratio of the spiked analyte/internal standard in
methanol: H2O, 1:1 (n = 3). The QC sample was tested in triplicate
on each of six different serum batches. CV% was calculated as
mentioned in section 2.6.4.
2.6.6. Stability
Analyte stability was evaluated for analytes in both solution and
serum. Diluted standard solution stability was evaluated after 6 h
at room temperature and after 9 days storage at 4 C for all eight
analytes at LLOQ and ULOQ levels and for the internal standard
working solution. The stability was assessed in triplicate by
comparing peak area of the old (6 h and 9 days) solutions with
freshly prepared from stock stored at 20 C.
In order to ensure that the processed samples were stable
during the analytical run, post-preparative stability was studied at
the three QC levels for 43 h at the auto sampler temperature of 4 C
by analyzing five samples per QC level. Analyte stability in serum
was determined by preparing samples at two QC levels (low and
high) and analyzing six serum samples containing a known
concentration of each analyte as follows: bench top stability at
room temperature after 21 h, after three freeze-thaw cycles (24 h at
80 C with thaw unassisted at room temperature), and long-term
stability at 80 C after 28 weeks of storage. In order to evaluate
the stability, the concentrations in these samples were compared
to the nominal values by running a freshly prepared calibration
curves. The accuracy should fall within the 85–115% acceptance
criteria and RSD not to exceed 15%
3. Results and discussion
3.1. Method development
In the development of a comprehensive pharmacokinetic
technique determining parent drug and metabolites, the challenge
is to separate all of these compounds, while achieving the highest
sensitivity without compromising linearity. Several mobile phases
were evaluated including different organic modifiers (methanol,
acetonitrile and methanol/acetonitrile mixtures) at various con-
centrations in water, as well mobile phases containing ammonium
formate and/or formic acid without organic modifier. The Prodigy
Phenomenex C18 analytical columns were also evaluated. Optimi-
zation of sample preparation according to recovery was also
performed, varying volumes of MTBE, as well as evaluating acidic
and neutral reconstitution solutions. The best method was then
selected based on the separation of all metabolites as well as based
on the analytical qualities of linearity and sensitivity.
3.2. Optimization of the mass analyzer and chromatographic
conditions
Because these metabolites are steroidal compounds containing
a pyridyl moiety, the mass analyzer was operated with electro-
spray ionization in the positive mode. The parameters were
optimized to ensure that the highest sensitivity possible would be
achieved. The settings of the mass spectrometric parameters used
in the optimized method are listed in Section 2.5, and the analyte
mass transitions are given in Table 2.
3.3. Optimization of the chromatographic conditions
Many of the metabolites are isomeric compounds, and thus it is
not possible to distinguish between them based on their MRM
transitions. Therefore, we separated the metabolites (as well as the
parent compound) by chromatography. Optimization of isocratic
chromatographic conditions was done investigating the effect of
various mobile phase components at different concentrations. A
mobile phase of 35% water mixed with 65% methanol/acetonitrile
(60:40) (both containing 0.1% formic acid) resulted in the
optimized chromatographic performance, separating the parent
compound and metabolites, as shown in Fig. 2. It should be noted
that the method was able to resolve diastereomeric metabolites
with a C18 column, not requiring chiral columns for separation of
these stereoisomers. The employment of a methanol/acetonitrile
mixture was critical to achieve this separation, as methanol or
acetonitrile as sole organic modifiers in the mobile phase did not
resolve the chiral compounds.
3.4. Method validation
The method was validated according to FDA guidelines. As
discussed below, all criteria of the guidelines were met for the
present method. All the analytes were stable in solution and serum,
meeting the stability criterion. The criteria for linearity, accuracy
and precision fell within the acceptance criteria. The method gave
excellent recovery without matrix effects or interference.
3.4.1. Linearity
Six sets of calibrators in the same serum matrices were used to
generate calibration plots to evaluate the linearity for each analyte.
Each calibration curve consisted of seven non-zero points. The plot
of the response ratio (analyte peak area over internal standard
peak area) versus the analyte concentration was linear, the R2
values for all analytes were 0.9979. The mean values for slope,
intercept and R2 values for each analyte are listed in Table 3.
3.4.2. Accuracy, precision, and LLOQ
The results for inter- and intra-day precision and accuracy
determination are given in Table 4. Five replicates of each QC
Table 3
Mean values for slope, intercept and R2 values obtained from six different
calibration curves.
Analyte Slope Intercept R2
Abiraterone 1.80E-02 8.17E-03 0.9990
D4A 2.47E-02 3.00E-06 0.9996
3-keto-5a-Abi 2.00E-02 1.04E-04 0.9995
3a-OH-5a-Abi 2.16E-02 6.33E-05 0.9995
3b-OH-5a-Abi 2.56E-02 1.21E-04 0.9996
3-keto-5b-Abi 1.15E-02 3.80E-05 0.9995
3a-OH-5b-Abi 1.26E-02 3.67E-05 0.9995
3b-OH-5b-Abi 2.03E-03 5.00E-06 0.9991
Fig. 2. Chromatogram for abiraterone and its metabolites. The results were obtained by injecting 10 mL of 50 ng/mL standard solutions for A, Abi; B, D4A; C, 3-keto-5a-Abi; D,
3a-OH-5a-Abi; E, 3b-OH-5a-Abi; F, 3-keto-5b-Abi; G, 3a-OH-5b-Abi; and H, 3b-OH-5b-Abi.
sample were prepared in three different days, to test the method
accuracy and precision. The CV% of the 5 replicates determining
intra-day precision and the CV% of the 15 replicates determining
inter-day precision for the eight analytes ranges between 0.99–
10.75% and 2.84–12.18%, respectively. The accuracy values for
intra-day and inter-day fall between 91.7–107.4% and 93.8–103.5%,
respectively. Five LLOQ samples were prepared in the first batch,
and the intraday accuracy mean values were 85.3–111.2% and CV%
2.63–16.89%. All the results fall within the FDA acceptance criteria.
3.4.3. Selectivity
Six LLOQ samples, each prepared in different serum batches,
were compared to the blank samples showed that the serum was
free from interference. The MRM chromatograms for the six
representative blank samples compared to the MRM chromato-
grams of LLOQ samples of Abi and its 7 metabolites are shown in
Fig. 3. The analyte peak in the spiked LLOQ samples ranged from a
factor 6.7–592.6 greater than the blank serum matrix with largest
interference peak at the same retention time, meeting the LLOQ
requirement being a factor greater than 5 for the technique to be
judged free of interference.
3.4.4. Recovery
Three QC levels were used to study the relative recovery, which
is determined by a percent ratio of the analyte/internal standard
peak area of a spiked sample before extraction over the analyte/
internal standard peak area of a spiked sample after extraction. The
results should be consistent, precise, and reproducible. The
recovery was calculated as the mean of three triplicates for each
analyte at each QC level. Recovery results were good, ranging from
85.1–105.2% (Table 5). CV% given in Table 5 ranged from 1.09–
13.47% for all QC samples, meeting the 15% CV% criterion for
acceptable recovery.
3.4.5. Matrix effect
The matrix effect is quantified as a matrix factor percent (MF%)
by calculating the ratio the peak area ratio of analyte/internal
standard of a QC low sample (post-extraction addition of analyte)
over the peak area ratio of analyte/internal standard in a methanol/
water solution. Matrix effect results are given in Table 5, showing
that the technique is essentially free of interference, with results
ranging from 88.5–114.7% for QC low samples.
Table 4
Intra- and inter-day accuracy and precision for abiraterone and its metabolites in LLOQ and QC samples.













Abirateroneb 2.05  0.06 102.7 2.89 n.a n.a n.a
6.40  0.17 106.8 2.65 6.21  0.31 103.5 4.95
203.8  4.2 102.0 2.06 206.3  5.9 103.3 2.84
316  12 98.7 3.86 317  22 99.1 6.80
D4Ac 0.111  0.004 111.2 3.89 n.a n.a n.a
0.307  0.024 102.3 7.76 0.297  0.020 98.9 6.68
10.02  0.19 100.2 1.86 9.74  0 0.38 97.4 3.94
16.4  0.5 102.3 3.02 16.0  1.0 100.1 6.35
3-keto5a-Abic 0.111  0.004 111.0 3.43 n.a n.a n.a
0.322  0.005 107.4 1.56 0.301  0.02 100.1 7.86
10.32  0.29 103.2 2.86 9.87  0.5 98.7 5.03
16.8  0.8 104.9 4.68 16.5  1.2 103.1 7.56
3a-OH5a-Abic 0.106  0.010 106.2 9.23 n.a n.a n.a
0.314  0.020 104.6 5.96 0.304  0.030 101.5 9.45
9.91  0.44 99.1 4.41 9.39  0.59 93.9 6.33
14.8  0.7 92.6 4.97 15.1  1.2 94.5 7.61
3b-OH5a-Abic 0.103  0.003 103.0 2.63 n.a n.a n.a
0.305  0.010 101.5 4.21 0.301  0.01 100.3 4.66
9.92  0.20 99.2 2.07 9.86  0.39 98.6 3.99
16.0  0.7 99.9 4.63 16.1  1.0 100.6 6.51
3-keto5b-Abic 0.106  0.004 106.4 4.13 n.a n.a n.a
0.316  0.008 105.4 2.56 0.303  0.03 101.0 8.77
9.95  0.27 99.5 2.70 9.56  0.44 95.6 4.61
15.1  0.5 94.2 3.61 15.5  1.2 96.5 7.80
3a-OH5b-Abic 0.108  0.004 108.4 4.26 n.a n.a n.a
0.308  0.020 102.6 6.74 0.301  0.02 100.4 7.55
9.74  0.29 97.4 2.98 9.37  0.40 93.8 4.26
15.0  0.7 93.8 4.65 15.3  1.1 95.8 7.46
3b-OH5b-Abic 0.085  0.010 85.3 16.89 n.a n.a n.a
0.275  0.030 91.7 10.75 0.29  0.03 97.6 12.18
9.68  0.09 96.8 0.99 9.76  0.36 97.6 3.67
14.9  0.8 93.3 5.60 16.0  1.5 99.7 9.66
a Measured Concentration in ng/ml.
b Nominal Concentrations: (LLOQ = 2, QC Low = 6, Mid = 200, and High = 320 ng/mL).
c Nominal Concentrations: (LLOQ = 0.1, QC Low = 0.3, Mid = 10, and High = 16 ng/mL).
Fig. 3. Representative chromatogram of selectivity studies comparing blank samples (left chromatograms) matched to LLOQ (right chromatograms) for A, Abi; B, D4A; C, 3-
keto-5a-Abi; D, 3-keto-5b-Abi; E, 3a-OH-5a-Abi; F, 3a-OH-5b-Abi; G, 3b-OH-5a-Abi; and H, 3b-OH-5b-Abi.
Table 5
Matrix effect and recovery for abiraterone and its metabolites.
MF% (n = 18) Recovery% (n = 3)
QC low QC low QC Mid QC High
Mean (%) RSD (%) Mean (%) RSD (%) Mean (%) RSD
(%)
Mean (%) RSD (%)
Abi 114.7 5.04 95.7 6.54 91.7 1.49 93.4 4.65
D4A 88.5 5.99 105.2 4.78 99.0 3.39 94.6 7.81
3-keto-5a-Abi 96.1 5.22 91.6 7.47 89.1 7.62 97.7 9.12
3a-OH-5a-Abi 92.0 5.05 91.2 7.48 85.1 4.51 95.1 5.61
3b-OH-5a-Abi 99.4 4.57 88.5 6.87 86.9 2.12 92.1 5.78
3-keto-5b-Abi 93.2 8.31 91.0 13.47 87.1 6.33 96.3 6.39
3a-OH-5b-Abi 92.0 6.74 86.0 8.47 85.1 1.09 91.1 5.64
3b-OH-5b-Abi 100.0 11.13 96.6 11.50 86.3 4.28 91.4 8.16
RSD% – relative standard deviation percent which is the same as CV%.
3.4.6. Stability
Analytes were stable in the diluted solution stored at room
temperature for 6 h 98.5–115.0% and at 4 C for 9 days 83.2–109.5%
as given in Table 6. Results of serum-based stability studies
employing QC samples are given in Table 7. Post-preparative
stability in which the QC samples were stored in the autosampler
at 4 C for 43 h were found to be acceptable 96.1–103.3%. Short-
term (21 h) stability of all analytes in the prepared QC samples at
each concentration were within the acceptance criteria 88.2–
114.8% for the determined mean concentration values. Even
though all analytes did show a decrease in concentration when
subjected to three freeze-thaw cycles 86.3–96.7% and long term
stability 86.7–95.6%, the results were less than 15%, which is within
the criteria for accuracy.
4. Conclusion
We have developed and validated an LC–MS/MS MRM method
for the determination and accurate quantification of Abi and its
seven steroidal metabolites in human serum. To our knowledge,
this is the first published report of a method to determine Abi
metabolites that result from steroidogenic metabolism. The
validated LC–MS/MS method resolved and quantitated all the
metabolites despite the similarity in their structures, including
resolving diastereomers, which precludes analysis of co-eluting
isomers based solely on their MRM transitions. Reversed-phase
chromatographic conditions were identified to accomplish the
separation of all metabolites and their subsequent accurate
quantification. This validated method can be applied to determine
Abi and the aforementioned metabolites in human serum in
clinical trials in which patients are treated with AA.
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Long-term stability 28 weeks
QC Low QC Mid QC High QC Low QC High QC Low QC High QC Low QC
High
Abi1 Concentration 5.9 203.4 314.6 5.3 293.8 5.4 284.9 5.7 290.7
Accuracy% 97.8 101.7 98.3 88.2 91.8 89.5 89.0 95.5 90.8
% RSD 3.26 0.75 3.04 6.03 1.97 11.38 9.45 0.82 2.28
D4A2 Concentration 0.3 9.6 16.0 0.3 18.4 0.3 15.3 0.3 14.2
Accuracy% 96.7 96.1 100.3 100.0 114.8 86.7 95.8 90.0 88.6
% RSD 3.68 2.87 2.67 3.03 1.86 8.82 11.71 3.64 1.42
3-keto-5a-Abi2 Concentration 0.3 10.0 16.3 0.3 15.7 0.3 14.7 0.3 14.4
Accuracy% 100.0 100.2 101.6 93.3 98.1 86.7 91.6 86.7 90.1
% RSD 4.49 1.25 3.95 8.04 2.57 12.84 14.11 5.90 5.59
3a-OH-5a-Abi2 Concentration 0.3 10.1 16.3 0.3 15.8 0.3 14.1 0.3 14.2
Accuracy% 103.3 100.7 102.0 96.7 98.7 86.7 88.2 86.7 88.6
% RSD 3.48 2.02 3.89 7.16 3.40 9.82 14.26 7.32 4.34
3b-OH-5a-Abi2 Concentration 0.3 9.9 15.7 0.3 15.2 0.3 13.9 0.3 14.1
Accuracy% 100.0 98.7 98.1 90.0 95.1 86.7 86.7 86.7 87.9
% RSD 3.16 1.37 4.20 10.28 2.22 14.55 11.27 4.58 2.50
3-keto-5b-Abi2 Concentration 0.3 10.2 16.3 0.3 16.3 0.3 14.2 0.3 14.4
Accuracy% 103.3 101.7 102.0 100.0 101.8 93.3 88.9 86.7 90.1
% RSD 6.40 1.62 4.03 7.58 3.66 14.57 13.44 4.92 4.26
3a-OH-5b-Abi2 Concentration 0.3 9.6 15.6 0.3 16.1 0.3 13.8 0.3 15.0
Accuracy% 100.0 96.2 97.5 96.7 100.8 86.7 86.3 90.0 93.5
% RSD 4.81 2.06 4.20 7.77 2.29 10.66 12.19 3.65 3.53
3b-OH-5b-Abi2 Concentration 0.3 9.8 16.1 0.3 16.5 0.3 14.4 0.3 14.7
Accuracy% 103.3 98.2 100.4 93.3 103.0 96.7 89.8 93.3 91.9
% RSD 7.82 1.27 3.19 10.44 5.30 14.41 13.84 5.21 3.56
RSD% = relative standard deviation% is the same as CV%; 1 Nominal Concentrations: (QC Low = 6, Mid = 200, and High = 320 ng/mL); 2 Nominal Concentrations: (QC Low = 0.3,
Mid = 10, and High = 16 ng/mL).
Table 6
Stock stability for abiraterone, its metabolites and the internal standard.
6 hours at RT (n = 3) 9 days at 4 C (n = 3)
LLOQ (%) ULOQ (%) LLOQ (%) ULOQ (%)
Abi 98.5 103.5 109.5 98.4
D4A 100.2 102.4 91.1 86.9
3-keto-5a-Abi 112.1 103.7 101.6 88.4
3a-OH-5a-Abi 103.8 102.7 97.9 85.7
3b-OH-5a-Abi 105.2 102.1 101.7 89.3
3-keto-5b-Abi 107.6 103.7 97.5 83.2
3a-OH-5b-Abi 104.1 103.3 105.0 85.4
3b-OH-5b-Abi 115.0 104.6 95.4 89.7
Internal standard 105.7 86.2
RT, Room temperature.
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